AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03801460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remotely administered physiological reconditioning program
Description: Patients assigned to intervention arm will be provided a personalized, tailored and graduated exercise program to improve physical strength and conditioning.
Study NCT02609009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation Therapy
Description: Intervention will consist of Diversified type adjustments. Patients will be assigned to the nearest participating chiropractic clinic and will have a complete standardized examination on their first visit. Patient will then receive a maximum of 12 treatments (3x per week for a period of 4 weeks).
Study NCT02609009 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Medical Care
Description: Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises. If recommended, physical therapy will be provided by the hospital physical therapy services. Physical therapy might include treatments such as massage, different electrotherapy, postural repositioning, exercises, etc
Study NCT01278862 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Veneer
Description: CAD/CAM milled Lava crown with lab fabricated veneer
Study NCT06629714 — intervention group
Intervention type: OTHER
Intervention: Exposure: emotional distress status
Description: The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a sum score of PHQ-9 and GAD-7 ≥ 10 were categorized as the stressed group.
Study NCT06714487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive stimulation through games
Description: cognitive stimulation through games
Study NCT03680794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sampling of ophthalmic liquid
Description: aqueous sampling for patients with cataract surgery or vitreous sampling for patients with posterior segment surgery
Study NCT04355091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Description: It combines cognitive therapy, acceptance and stability therapy, and acupuncture point stimulation, and is based on manual stimulation of acupuncture points specific to Shiatsu or other acupressure massage forms, rather than using acupuncture needles.
Study NCT00219336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-guided Motivational Intervention
Description: Using a randomized two-group design, a self-guided motivational intervention based on Project CHOICES will be compared to an informational only intervention, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS.
Study NCT00219336 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational Only
Description: Using a randomized two-group design, an informational intervention using a brochure from the CDC will be compared to a self-guided motivational intervention based on Project CHOICES, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS
Study NCT03011372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.~Participants will receive either the intermittent dose (as written) or continuous dosing.
Study NCT04817085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visant Medical Canalicular Plug
Description: Plug is inserted into the inferior canaliculi and assessed for 6 months
Study NCT04817085 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available canalicular plug
Description: Plug is inserted into the inferior canaliculi and assessed for 6 months
Study NCT03137342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pepped on PrEP Package
Description: A counseling and problem-solving adherence intervention with a Behavioral Activation approach to re-engage participants in safe but pleasurable activities in life and addresses stimulant abuse as well as associated factors, including depression, as barriers to optimal PrEP adherence.
Study NCT03643354 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Epley maneuver/Barbeque maneuver
Description: Subjects will be rotated using the Rotundum Device to perform the previously described maneuvers Epley/Barbeque to evaluate the presence of BPPV.
Study NCT02620072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Insulin
Description: Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 67.5 mg or placebo for the following 9 months of the treatment period. Follow-up will continue for 24 months after the last administration of treatment.
Study NCT02620072 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Total of 12 months intervention period; daily administration of insulin or placebo capsules containing filling substance (microcrystalline cellulose). Follow-up will continue for 24 months after the last administration of treatment.
Study NCT02624778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3002813
Description: Administered IV
Study NCT00628979 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT
Description: cognitive- behavioral treatment for panic disorder.
Study NCT02624778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT01266044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture - Group 1
Description: Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment.
Study NCT01266044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture - Group 2
Description: Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment.
Study NCT01266044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard oral care recommendations. Participants in all groups will receive the same recommendations.
Study NCT01266044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard oral care recommendations. Participants in all groups will receive the same recommendations.
Study NCT01266044 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard oral care recommendations. Participants in all groups will receive the same recommendations.
Study NCT01266044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
Study NCT01266044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
Study NCT01266044 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
Study NCT03483337 — intervention group
Intervention type: OTHER
Intervention: MRI examinations
Description: Patients will be imaged on a 1.5 T or 3 T MR scanner either from GE or Philips. Patients will receive a test-retest scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at main campus, will also be imaged weekly during their course of treatment.
Study NCT03483337 — intervention group
Intervention type: OTHER
Intervention: MRI examinations
Description: Patients will be imaged on a 1.5 T or 3T MR scanner within one week prior to treatment initiation and at two months and four months after treatment completion (+/- 1 week).
Study NCT04452955 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRL3-zumab
Description: Starting dose of 6 mg/kg will be administered as IV infusion over 60 minutes every 2 weeks (±2 days)
Study NCT04091672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control Intervention (Conventional Autograft)
Description: Meshed split-thickness skin graft, with standardized wound dressings (Telfa™ Clear and Xeroform™)
Study NCT04091672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Intervention (RECELL + more widely meshed autograft)
Description: More widely meshed split-thickness skin graft, Spray-on Skin™ Cells prepared using RECELL, and standardized wound dressings (Telfa™ Clear and Xeroform™)
Study NCT04073355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Smartphone-delivered physical activity intervention
Study NCT03404336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Well-Being Therapy
Description: Session 1: identifying and setting episodes of wellbeing into situational context. Session 2: identifying interfering thoughts and behaviors. Session 3: illustrating autonomy, reflecting and practicing it. Session 4: illustrating environmental mastery, reflecting and practicing it. Session 5: illustrating positive relations with others, reflecting and practicing it. Session 6: illustrating personal growth, reflecting and practicing it. Session 7: illustrating self-acceptance, reflecting and practicing it. Session 8: illustrating purpose in life, reflecting and practicing it.
Study NCT03404336 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control condition
Description: Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drugs misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
Study NCT02683824 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT02683824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02683824 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI scan
Description: Undergo PET/MRI scan
Study NCT02683824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FP-R01-MG-F2
Description: radioactive tracer
Study NCT02883686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alma
Description: Alma peer-mentoring
Study NCT00866788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: Administered by subcutaneous injection
Study NCT03804411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Automatic system guided treatment
Description: Addition of: 1A -vildagliptin 100 mg/day 2A - sitagliptin 100 mg/day, 3A- dapagliflozin 10 mg/day 4A- empagliflozin 10 mg/day 5A- liraglutide 1,2-1,8 mg/day 6A- exenatide 20 μg/day 7A - glimepiride 8A - gliclazide
Study NCT03804411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Addition of:~1. B -vildagliptin 100 mg/day~2. B - sitagliptin 100 mg/day,~3. B- dapagliflozin 10 mg/day~4. B- empagliflozin 10 mg/day~5. B- liraglutide 1,2-1,8 mg/day~6. B- exenatide 20 μg/day~7. B - glimepiride~8. B - gliclazide
Study NCT02807753 — intervention group
Intervention type: OTHER
Intervention: Ankle and Knee Ultrasound Joint Assessment
Description: Ultrasound Examination of the ankles and knees
Study NCT02807753 — intervention group
Intervention type: OTHER
Intervention: Ankle and Knee Magnetic Resonance Imaging
Description: Ankle and Knee Magnetic Resonance Imaging
Study NCT04397393 — intervention group
Intervention type: DRUG
Intervention: Midazolam
Description: Dosage of Midazolam (in mg) needed to achieve satisfactory level of sedation to perform OPU
Study NCT00909766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, Oral, 30 mg, once daily, 28 days
Study NCT00909766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, Oral, 100 mg, once daily, 28 days
Study NCT00909766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, oral, 300 mg, once daily, 28 days
Study NCT00909766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, oral, 600 mg, once daily 28 days
Study NCT00909766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, oral, 1200 mg, once daily, 28 days
Study NCT00909766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, Oral, to be determined, once daily, 28 days
Study NCT00909766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 28 days
Study NCT03485846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlaprevir
Description: 100 mg, oval shaped, concave, yellow film-coated, tablets taken as 200 mg per os daily
Study NCT03485846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg, tablets, taken as 100 mg per os daily
Study NCT03485846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: 60 mg, tablets, taken as 60 mg per os daily
Study NCT00673764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Ultra Lubricant Eye Drops
Description: Systane Ultra Lubricant Eye Drops 1 drop each eye one time
Study NCT00866788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: omalizumab
Description: Administered by subcutaneous injection
Study NCT00673764 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optive Lubricant Eye Drops
Description: Optive Lubricant Eye Drops 1 drop each eye one time
Study NCT03129230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: free nonvascularized fibula autograft
Description: Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck between Aug. 2012 and Sep. 2016. All the patients were given supplementary skeletal traction through supracondyle of femur for 4 weeks to 6 weeks after the resections.
Study NCT04472858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: dose escalation: Donafenib 100 mg QD/100 mg BID/200 mg BID (p.o.). dose expansion: Patients will be assigned to specific tumor types and treated at the recommended dose for dose escalation.The recommended dose for dose escalation will be determined by the dose escalation study.
Study NCT04472858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1001
Description: CS1001 will be administrated by intravenous (i.v.) infusion once every 28 days
Study NCT01978652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon Beta-1a
Description: As specified in the treatment arm
Study NCT01031992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid first, than placebo
Description: For 3 months Tranexamic acid 3 times daily 1 g taken orally, followed by placebo for 3 months.
Study NCT01031992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First placebo, than Tranexamic acid.
Description: First placebo for 3 months, than tranexamic acid 3 times daily 1 g for 3 months.
Study NCT01938352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR8020
Description: CR8020 15 mg/kg, administered by intravenous infusion
Study NCT01938352 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (hydrous dextrose in water for injection), administered by intravenous infusion
Study NCT03561922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RETINA IMPLANT Alpha AMS
Description: Implantation of the subretinal RETINA IMPLANT Alpha AMS
Study NCT00432055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Botox)
Study NCT00432055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (saline)
Study NCT00414349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical analgesic
Description: max. 3 plasters per day for PHN patients max. 4 plasters per day for DPN patients
Study NCT00414349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral intake
Description: 300 to 600 mg per day taken orally
Study NCT00414349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical analgesic
Description: 3 plasters for PHN patients per day 4 plasters for DPN patients per day
Study NCT02996019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab will be administered at a dose of 105 milligrams (mg).
Study NCT02996019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etrolizumab
Description: Etrolizumab will be administered at a dose of 105 milligrams (mg).
Study NCT02996019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-Injector (AI)
Description: The pre-filled AI will be used to administer etrolizumab.
Study NCT02996019 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prefilled Syringe With Needle Safety Device (PFS-NSD)
Description: The PFS-NSD will be used to administer etrolizumab.
Study NCT04060914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: Ticagrelor 90 mg plus aspirin for 12 months
Study NCT04060914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg/60mg
Description: 1 month after treatment with ticagrelor 90 mg plus aspirin, followed by treatment with ticagrelor 60 mg plus aspirin for 11 months
Study NCT04060914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg
Description: Clopidogrel 75mg plus aspirin for 12 months
Study NCT04258280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and counseling
Description: Education includes a workbook, counseling includes peer support.
Study NCT04258280 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education includes a workbook.
Study NCT00866788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants received a single subcutaneous placebo injection on Day 0 of the study.
Study NCT00866788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 antihistamines
Description: Patients received one of the following: Cetirizine 10 mg once per day (QD), Levocetirizine dihydrochloride 5 mg QD, Fexofenadine 60 mg twice per day or 180 mg QD, Loratadine 10 mg QD or Desloratadine 5 mg QD
Study NCT00866788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: H1 antihistamines
Description: Patients received one of the following: Cetirizine 10 mg once per day (QD), Levocetirizine dihydrochloride 5 mg QD, Fexofenadine 60 mg twice per day or 180 mg QD, Loratadine 10 mg QD or Desloratadine 5 mg QD
Study NCT00866788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine was provided and used on an as-needed basis (25 mg per dose)
Study NCT00866788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine was provided and used on an as-needed basis (25 mg per dose)
Study NCT01509365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: 2 tablets of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
Study NCT01509365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: 1 tablet of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
Study NCT03940287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Muscle energy technique will be given in two different position. For anterior in- nominate rotation and posterior in- nominate rotation patient position will be in supine lying position.~For weakened muscle,piriformis application the patient should be side-lying position, close to the edge of the table, affected side uppermost, both legs flexed at hip and knee.~The therapists stand facing the patient at hip level,then patient should be close enough to the edge of the table for the therapist to stabilize the pelvis against his trunk. The angle of hip flexion should not exceed 60°, and then places one hand on the contralateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis.~Isometric contraction should be hold for 3-5 second and that particular method will be repeated for 7-10 times.